Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan 7;20(1):43.
doi: 10.1186/s13019-024-03316-3.

Clinical efficacy and hemodynamic effects of levosimendan in cardiac surgery patients after surgery

Meiling Zhao  1 , Yunfeng Hou  2 , Meng Yuan  1 , Shuang Ma  1 , Yifeng Yue  3
Affiliations
Randomized Controlled Trial

Clinical efficacy and hemodynamic effects of levosimendan in cardiac surgery patients after surgery

Meiling Zhao et al. J Cardiothorac Surg. .

Abstract

Objective: To investigate the therapeutic effect of levosimendan on hemodynamics in patients undergoing major cardiac surgery and presenting with acute postoperative heart failure.

Methods: The subjects of the study were 160 patients with severe cardiac conditions who underwent surgery and had acute heart failure. Eighty cases each were assigned to the research and control groups using a random number table. Document the general patient data for each of the two groups; compare the clinical outcomes of the two groups. The hemodynamic states of the two groups were compared both before and after therapy. 48 h after surgery, echocardiography was performed in both groups to determine cardiac function. 48 h after surgery, N-terminal pro-brain B-type natriuretic peptide (NT-Pro-BNP) levels were compared between the two groups.

Results: The overall effective rate was significantly higher in the research group (92.5%) compared to the control group (76.25%, P < 0.05). Post-treatment, the research group demonstrated a significant reduction in CVP (9.25 ± 2.11 cmH2O vs. 11.36 ± 3.08 cmH2O, P < 0.001), heart rate (100.30 ± 8.69 bpm vs. 105.74 ± 7.69 bpm, P < 0.001), and lactic acid levels (1.68 ± 0.59 mmol/L vs. 2.69 ± 0.55 mmol/L, P < 0.001). The research group also showed improvements in SBP (117.23 ± 8.74 mmHg vs. 113.25 ± 7.55 mmHg, P = 0.002) and urine output (4.21 ± 1.76 mL/kg/h vs. 3.65 ± 1.23 mL/kg/h, P = 0.021). Cardiac function indicators 48 h after surgery indicated a higher LVEF (55.21 ± 8.04% vs. 47.18 ± 6.60%, P < 0.001) and lower LVEDVi and LVESVi in the research group (P < 0.001 for both). NT-Pro-BNP levels were significantly lower in the research group (6010.19 ± 1208.52 pg/mL vs. 9663.21 ± 2391.34 pg/mL, P < 0.001). The incidence of complications was lower in the research group (5% vs. 22.5%, P = 0.001).

Conclusion: Cardiac surgery patients are prone to complications with acute heart failure after surgery. Treatment with levosimendan can significantly improve clinical efficacy and reduce complications. It can also effectively improve patients' cardiac function and promote hemodynamic stability.

Keywords: Acute cardiac insufficiency; Cardiac surgery; Clinical efficacy; Hemodynamics; Levosimendan.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study is approved by the Ethics Committee of Zibo Central Hospital. Signed informed consent was also obtained from all participants. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Comparing the two groups’ clinical outcomes
Fig. 2
Fig. 2
Contrast of the two groups’ post-treatment CVP, Systolic blood pressure, urine volume, heart rate, and lactic acid level
Fig. 3
Fig. 3
Contrast of the two groups’ LVEDVi, LVESVi, and LVEF values 48 h following Surgery
Fig. 4
Fig. 4
Comparison of NT-Pro-BNP levels between the two groups
Fig. 5
Fig. 5
Contrast of complications between the two groups
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abraham J, Blumer V, Burkhoff D, Pahuja M, Sinha SS, Rosner C, Vorovich E, Grafton G, Bagnola A, Hernández-Montfort J, Kapur NK. Heart failure-related cardiogenic shock: pathophysiology, evaluation and management considerations. J Cardiac Fail. 2021;27(10):1126–40. 10.1016/j.cardfail.2021.08.010. - PubMed
    1. Akhtar S, Hassan MQ, Siddiqui A, Alavudeen SS, Afzal O, Altamimi ASA, Rahman SO, Khurana M, Ahsan MJ, Kumar A, Tabassum F. Levosimendan: mechanistic insight and its diverse future aspects in cardiac care. Acta Cardiol. 2022;78(2):170–87. 10.1080/00015385.2022.2115761. - PubMed
    1. Burkhoff D, Rich S, Pollesello P, Papp Z. Levosimendan-induced venodilation is mediated by opening of potassium channels. Esc Heart Fail. 2021;8(6):4454–64. 10.1002/ehf2.13669. - PMC - PubMed
    1. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options. Crit Care. 2020. 10.1186/s13054-020-2743-8. - PMC - PubMed
    1. Compagner CT, Wysocki CR, Reich EK, Zimmerman L, Holzhausen JM. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Am J Emerg Med. 2022;62:49–54. 10.1016/j.ajem.2022.10.001. - PubMed

Publication types

MeSH terms